12:01 PM EST - Algernon Pharmaceuticals Inc. : Has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to conduct a phase 2 COVID-19 clinical trial using its re-purposed drug NP-120 (Ifenprodil). Algernon Pharmaceuticals Inc.
shares AGN:CNX are trading up $0.155 at $0.46.
